47 research outputs found
Π₯Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° HCV-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Ρ ΠΎΠ½ΠΊΠΎΠ³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ
Objective: clinical and laboratory characteristics of HCV infection in patients with oncohematological malignancies. Materials and Methods: The study included 106 patients with a positive serum HCV antibody (anti-HCV) test result, who were examined or treated in 5 specialized oncohematological units of different hospitals in Saint Petersburg in 2018β2019.Laboratory tests included: ALT and AST activity, qualitative (with sensitivity of 60 IU/ml) and quantitative determination of HCV RNA, as well as HCV genotyping by real-time PCR. The presence and the grade of liver fibrosis according to the METAVIR scale were evaluated by indirect elastography on Fibroscan. Results: Men were predominant (62,2%), and most of patients (67%) were of young and middle age (18-59 years old). HCV infection was confirmed in 68% patients, and in 41.7% of them HCV genotype 3 was detected. HCV RNA was not detected in 32% cases, suggesting the spontaneous clearance of the virus. Severe liver fibrosis (F3) or cirrhosis (F4) were found in 40% patients with confirmed viremia. In most patients, the normal ALT activity level was registered. 86% patients diagnosed with HCV infection were followed up by an infectious disease specialist until the present study. 19% patients received antiviral therapy for HCV infection. Conclusion: A significant proportion of patients with advanced liver fibrosis and HCV 3 genotype, causing the greatest difficulties in antiviral treatment for HCV infection, was revealed. Prescription of direct-acting antiviral agents in the early terms after establishment of the diagnosis is reasonable.Π¦Π΅Π»Ρ: ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½Π°Ρ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° HCVΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΎΠ½ΠΊΠΎΠ³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Π° ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 106 Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠΌ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π½Π° Π°Π½ΡΠΈΡΠ΅Π»Π° ΠΊ HCV (anti-HCV) Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ, ΠΏΡΠΎΡ
ΠΎΠ΄ΠΈΠ²ΡΠΈΡ
ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈΠ»ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π² 5 ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΎΠ½ΠΊΠΎΠ³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠ΄Π΅Π»Π΅Π½ΠΈΡΡ
ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠΎΠ² Π‘Π°Π½ΠΊΡ-ΠΠ΅ΡΠ΅ΡΠ±ΡΡΠ³Π° Π² 2018β2019 Π³Π³.ΠΠ°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠ΅ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ°Π»ΠΎ: ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΠ»ΠΠ’ ΠΈ ΠΡΠΠ’, ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ (ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ β 60 ΠΠ/ΠΌΠ») ΠΈ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π ΠΠ HCV ΠΈ Π³Π΅Π½ΠΎΡΠΈΠΏΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ HCV ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΠ¦Π Π² ΡΠ΅ΠΆΠΈΠΌΠ΅ ΡΠ΅Π°Π»ΡΠ½ΠΎΠ³ΠΎ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ. ΠΠ°Π»ΠΈΡΠΈΠ΅ ΠΈ ΡΡΠ΅ΠΏΠ΅Π½Ρ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΏΠΎ ΡΠΊΠ°Π»Π΅ METAVIR ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π½Π΅ΠΏΡΡΠΌΠΎΠΉ ΡΠ»Π°ΡΡΠΎΠΌΠ΅ΡΡΠΈΠΈ Π½Π° Π°ΠΏΠΏΠ°ΡΠ°ΡΠ΅ Fibroscan.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΡΡΠ΅Π΄ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΏΡΠ΅ΠΎΠ±Π»Π°Π΄Π°Π»ΠΈ ΠΌΡΠΆΡΠΈΠ½Ρ (62,2%), Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²ΠΎ Π±ΠΎΠ»ΡΠ½ΡΡ
(67%) ΠΌΠΎΠ»ΠΎΠ΄ΠΎΠ³ΠΎ ΠΈ ΡΡΠ΅Π΄Π½Π΅Π³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° (18-59 Π»Π΅Ρ). Π₯ΠΠ‘ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½ Ρ 68% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΈΠ· Π½ΠΈΡ
Ρ 41,7% Π²ΡΡΠ²Π»Π΅Π½ HCV Π³Π΅Π½ΠΎΡΠΈΠΏ 3. Π 32% ΡΠ»ΡΡΠ°Π΅Π² Π ΠΠ HCV Π½Π΅ Π²ΡΡΠ²ΠΈΠ»ΠΈ, ΡΡΠΎ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠΈΡΡ Π΅ΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ ΡΠ»ΠΈΠΌΠΈΠ½Π°ΡΠΈΡ Π²ΠΈΡΡΡΠ°. Π£ 40% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½Π½ΠΎΠΉ Π²ΠΈΡΠ΅ΠΌΠΈΠ΅ΠΉ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΡΠΉ ΡΠΈΡΡΠΎΠ· (F3) ΠΈΠ»ΠΈ ΡΠΈΠ±ΡΠΎΠ· ΠΏΠ΅ΡΠ΅Π½ΠΈ (F4). ΠΠΎΡΠΌΠ°Π»ΡΠ½Π°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΠ»ΠΠ’ ΠΎΡΠΌΠ΅ΡΠ΅Π½Π° Ρ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° Π±ΠΎΠ»ΡΠ½ΡΡ
. ΠΠ° Π΄ΠΈΡΠΏΠ°Π½ΡΠ΅ΡΠ½ΠΎΠΌ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠΈ Ρ Π²ΡΠ°ΡΠ°-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½ΠΈΡΡΠ° ΡΠΎΡΡΠΎΡΠ»ΠΈ 86% ΠΎΡ ΡΠΈΡΠ»Π° Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π½ΡΠΌ Π΄ΠΈΠ°Π³Π½ΠΎΠ·ΠΎΠΌ Π₯ΠΠ‘ Π΄ΠΎ Π½Π°ΡΡΠΎΡΡΠ΅Π³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. ΠΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π₯ΠΠ‘ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π° 19% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ².ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅: ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΈΠ΅ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π΄ΠΎΠ»ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΏΡΠΎΠ΄Π²ΠΈΠ½ΡΡΡΠΌΠΈ ΡΡΠ°Π΄ΠΈΡΠΌΠΈ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΈ Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠΌ 3 HCV, ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»ΠΈΠ²Π°ΡΡΠΈΠΌ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠΈΠ΅ ΡΠ»ΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΏΡΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠΈ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π₯ΠΠ‘, ΠΊΠΎΡΠΎΡΡΠΌ ΡΠ΅Π»Π΅ΡΠΎΠΎΠ±ΡΠ°Π·Π½ΠΎ Π½Π°Π·Π½Π°ΡΠ°ΡΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ ΠΏΡΡΠΌΠΎΠ³ΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ Π² ΡΠ°Π½Π½ΠΈΠ΅ ΡΡΠΎΠΊΠΈ ΠΏΠΎΡΠ»Π΅ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ Π΄ΠΈΠ°Π³Π½ΠΎΠ·Π°
ΠΠ»ΠΈΡΠ½ΠΈΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΈ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π²ΠΈΡΡΡΠ° Π³Π΅ΡΠΏΠ΅ΡΠ° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° ΡΠΈΠΏΠ° 6 Π½Π° ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΡΠ°Π½Π½Π΅Π³ΠΎ ΠΏΠ΅ΡΠΈΠΎΠ΄Π° ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Π³Π΅ΠΌΠΎΠΏΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΡ ΡΡΠ²ΠΎΠ»ΠΎΠ²ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ Ρ ΠΎΠ½ΠΊΠΎΠ³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²
Β Β Objective.Β To assess the impact of CMV and HHV-6 reactivation on the course of early post-transplant period in patients with hematologic malignancies.Β Β Materials.Β Retrospective analysis of medical records of 339 patients with hematologic malignancies who received hematopoietic stem cell transplantation (HSCT) was performed, and markers of CMV and HHV-6 infections were detected (specific IgG, EIA). Blood and other materials from HSCT recipients were tested (PCR) for viral DNA in early post-transplant period (up to Day 100).Β Β Results.Β Reactivation of viral infections after HSCT was discovered in 177 patients (52,2 %): CMV-infection was detected in 23 %, HHV-6 in 17,4 %, CMV+HHV-6 in 11,6 % of HSCT recipients. CMV DNA was predominantly identified in blood, while HHV-6 DNA was more frequently discovered in GIT mucosa and bone marrow. 40 % of 99 patients with HHV-6 reactivation had concomitant CMV+HHV-6 reactivation. In this group, the clinical manifestation of infections was registered significantly more frequently. Febrile neutropenia was more frequent in HSCT recipients with CMV reactivation, sepsis and graft hypofunction were diagnosed more frequently in presence of HHV-6 and predominantly HHV-6+CMV infections. The direct correlation (using Spearmanβs method) between CMV and HHV-6 reactivation and terms of leukopoiesis recovery, engraftment terms, and transplant hypofunction was revealed. An impact of herpetic infections reactivation on the graft hypofunction and late recovery of leukopoiesis was confirmed using the logistic regression; its impact on the chimerism was revealed. In 72 % of cases, the graft failure in early post-transplant period occurred in patients with herpetic infections reactivation.Β Β Conclusion.Β HHV-6 and CMV reactivation in the early period after HSCT correlates with terms of leukopoiesis recovery, contributes to development of complications, and is an additional factor aggravating the course of the post-transplant period.Β Β Π¦Π΅Π»Ρ: ΠΎΡΠ΅Π½ΠΈΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ° ΠΈ Π²ΠΈΡΡΡΠ° Π³Π΅ΡΠΏΠ΅ΡΠ° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° 6 ΡΠΈΠΏΠ° Π½Π° ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΡΠ°Π½Π½Π΅Π³ΠΎ ΠΏΠΎΡΡΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΏΠ΅ΡΠΈΠΎΠ΄Π° Ρ ΠΎΠ½ΠΊΠΎΠ³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ².Β Β ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π Π΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ ΠΈΡΡΠΎΡΠΈΠΈ Π±ΠΎΠ»Π΅Π·Π½ΠΈ 339 ΠΎΠ½ΠΊΠΎΠ³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΊΠΎΡΠΎΡΡΠΌ Π²ΡΠΏΠΎΠ»Π½Π΅Π½Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΡ Π³Π΅ΠΌΠΎΠΏΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΠ²ΠΎΠ»ΠΎΠ²ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ ΠΈ Π²ΡΡΠ²Π»Π΅Π½Ρ ΠΌΠ°ΡΠΊΠ΅ΡΡ ΠΈΠ½ΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΡΡΠΈ ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ° ΠΈ Π²ΠΈΡΡΡΠ° Π³Π΅ΡΠΏΠ΅ΡΠ° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° 6 ΡΠΈΠΏΠ° (ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ IgG ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°). Π£ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π² ΡΠ°Π½Π½ΠΈΠΉ ΠΏΠ΅ΡΠΈΠΎΠ΄ (Π΄ΠΎ 100-Π³ΠΎ Π΄Π½Ρ) ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Π³Π΅ΠΌΠΎΠΏΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΠ²ΠΎΠ»ΠΎΠ²ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π»ΠΈ Π΄Π΅Π·ΠΎΠΊΡΠΈΡΠΈΠ±ΠΎΠ½ΡΠΊΠ»Π΅ΠΈΠ½ΠΎΠ²ΡΡ ΠΊΠΈΡΠ»ΠΎΡΡ Π²ΠΈΡΡΡΠΎΠ² Π² ΠΊΡΠΎΠ²ΠΈ ΠΈ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π°Ρ
(ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½Π°Ρ ΡΠ΅ΠΏΠ½Π°Ρ ΡΠ΅Π°ΠΊΡΠΈΡ).Β Β Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π Π΅Π°ΠΊΡΠΈΠ²Π°ΡΠΈΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Π³Π΅ΠΌΠΎΠΏΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΠ²ΠΎΠ»ΠΎΠ²ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Π° Ρ 177 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (52,2 %), ΠΈΠ· Π½ΠΈΡ
ΡΠΈΡΠ°ΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ β Ρ 23 %, Π²ΠΈΡΡΡΠ° Π³Π΅ΡΠΏΠ΅ΡΠ° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° 6 ΡΠΈΠΏΠ° β Ρ 17,4 % ΠΈ ΡΠΎΡΠ΅ΡΠ°Π½Π½Π°Ρ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡ β Ρ 11,6 % ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ². ΠΠ΅Π·ΠΎΠΊΡΠΈΡΠΈΠ±ΠΎΠ½ΡΠΊΠ»Π΅ΠΈΠ½ΠΎΠ²ΡΡ ΠΊΠΈΡΠ»ΠΎΡΡ ΡΠΈΡΠ°ΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ° ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΠΎΠ±Π½Π°ΡΡΠΆΠΈΠ²Π°Π»ΠΈ Π² ΠΊΡΠΎΠ²ΠΈ, Π΄Π΅Π·ΠΎΠΊΡΠΈΡΠΈΠ±ΠΎΠ½ΡΠΊΠ»Π΅ΠΈΠ½ΠΎΠ²ΡΡ ΠΊΠΈΡΠ»ΠΎΡΡ Π²ΠΈΡΡΡΠ° Π³Π΅ΡΠΏΠ΅ΡΠ° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° 6 ΡΠΈΠΏΠ° ΡΠ°ΡΠ΅ Π²ΡΡΠ²Π»ΡΠ»ΠΈ Π² ΡΠ»ΠΈΠ·ΠΈΡΡΡΡ
ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠ°Ρ
ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠ½ΠΎ-ΠΊΠΈΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΠΊΡΠ° ΠΈ ΠΊΠΎΡΡΠ½ΠΎΠΌ ΠΌΠΎΠ·Π³Π΅. ΠΠ· 99 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ΅Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠ΅ΠΉ Π²ΠΈΡΡΡΠ° Π³Π΅ΡΠΏΠ΅ΡΠ° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° 6 ΡΠΈΠΏΠ° Π² 40 % ΡΠ»ΡΡΠ°Π΅Π² Π±ΡΠ»Π° ΡΠΎΡΠ΅ΡΠ°Π½Π½Π°Ρ ΡΠ΅Π°ΠΊΡΠΈΠ²Π°ΡΠΈΡ ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ° ΠΈ Π²ΠΈΡΡΡΠ° Π³Π΅ΡΠΏΠ΅ΡΠ° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° 6 ΡΠΈΠΏΠ°. Π ΡΡΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π·Π½Π°ΡΠΈΠΌΠΎ ΡΠ°ΡΠ΅ ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π»ΠΈ ΠΌΠ°Π½ΠΈΡΠ΅ΡΡΠ°ΡΠΈΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ. ΠΠ· ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Π³Π΅ΠΌΠΎΠΏΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΠ²ΠΎΠ»ΠΎΠ²ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ ΡΠ°ΡΠ΅ ΡΠ΅Π±ΡΠΈΠ»ΡΠ½Π°Ρ Π½Π΅ΠΉΡΡΠΎΠΏΠ΅Π½ΠΈΡ Π±ΡΠ»Π° Π²ΡΡΠ²Π»Π΅Π½Π° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ CMV-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ, ΡΠ΅ΠΏΡΠΈΡ ΠΈ Π³ΠΈΠΏΠΎΡΡΠ½ΠΊΡΠΈΡ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° ΡΠ°ΡΠ΅ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠΎΠ²Π°Π»ΠΈ ΠΏΡΠΈ ΡΠ΅Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ Π²ΠΈΡΡΡΠ° Π³Π΅ΡΠΏΠ΅ΡΠ° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° 6 ΡΠΈΠΏΠ°, ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΡΠΎΡΠ΅ΡΠ°Π½Π½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ° ΠΈ Π²ΠΈΡΡΡΠ° Π³Π΅ΡΠΏΠ΅ΡΠ° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° 6 ΡΠΈΠΏΠ°. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° ΠΏΡΡΠΌΠ°Ρ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½Π°Ρ ΡΠ²ΡΠ·Ρ (ΠΌΠ΅ΡΠΎΠ΄ Π‘ΠΏΠΈΡΠΌΠ΅Π½Π°) ΠΌΠ΅ΠΆΠ΄Ρ ΡΠ΅Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠ΅ΠΉ ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ° ΠΈ Π²ΠΈΡΡΡΠ° Π³Π΅ΡΠΏΠ΅ΡΠ° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° 6 ΡΠΈΠΏΠ° ΠΈ ΡΡΠΎΠΊΠ°ΠΌΠΈ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠ°ΡΠ½ΠΎΠ³ΠΎ ΠΊΡΠΎΠ²Π΅ΡΠ²ΠΎΡΠ΅Π½ΠΈΡ, ΡΡΠΎΠΊΠ°ΠΌΠΈ ΠΏΡΠΈΠΆΠΈΠ²Π»Π΅Π½ΠΈΡ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° ΠΈ Π΅Π³ΠΎ Π³ΠΈΠΏΠΎΡΡΠ½ΠΊΡΠΈΠ΅ΠΉ. ΠΠ΅ΡΠΎΠ΄ΠΎΠΌ Π»ΠΎΠ³ΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅Π³ΡΠ΅ΡΡΠΈΠΈ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½ΠΎ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ Π³Π΅ΡΠΏΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ Π½Π° Π³ΠΈΠΏΠΎΡΡΠ½ΠΊΡΠΈΡ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° ΠΈ ΠΏΠΎΠ·Π΄Π½ΠΈΠ΅ ΡΡΠΎΠΊΠΈ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠ°ΡΠ½ΠΎΠ³ΠΎ ΠΊΡΠΎΠ²Π΅ΡΠ²ΠΎΡΠ΅Π½ΠΈΡ; Π²ΡΡΠ²Π»Π΅Π½ΠΎ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ Ρ
ΠΈΠΌΠ΅ΡΠΈΠ·ΠΌΠ°. Π 72 % ΡΠ»ΡΡΠ°Π΅Π² Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ΅Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠ΅ΠΉ Π³Π΅ΡΠΏΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ ΠΏΡΠΎΠΈΠ·ΠΎΡΠ»ΠΎ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΠ΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° Π² ΡΠ°Π½Π½ΠΈΠΉ ΠΏΠ΅ΡΠΈΠΎΠ΄ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Π³Π΅ΠΌΠΎΠΏΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΠ²ΠΎΠ»ΠΎΠ²ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ.Β Β ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π Π΅Π°ΠΊΡΠΈΠ²Π°ΡΠΈΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ Π²ΠΈΡΡΡΠ° Π³Π΅ΡΠΏΠ΅ΡΠ° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° 6 ΡΠΈΠΏΠ° ΠΈ ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ° Π² ΡΠ°Π½Π½ΠΈΠΉ ΠΏΠ΅ΡΠΈΠΎΠ΄ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Π³Π΅ΠΌΠΎΠΏΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΠ²ΠΎΠ»ΠΎΠ²ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ ΠΊΠΎΡΡΠ΅Π»ΠΈΡΡΠ΅Ρ ΡΠΎ ΡΡΠΎΠΊΠ°ΠΌΠΈ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠ°ΡΠ½ΠΎΠ³ΠΎ ΠΊΡΠΎΠ²Π΅ΡΠ²ΠΎΡΠ΅Π½ΠΈΡ, ΡΡΠ°ΡΡΠ²ΡΠ΅Ρ Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΠΈ ΡΠ»ΡΠΆΠΈΡ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ, ΠΎΡΡΠ³ΠΎΡΠ°ΡΡΠΈΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎΡΡΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΏΠ΅ΡΠΈΠΎΠ΄Π°
Characteristics of HCV infection in oncohematological patients
Objective: clinical and laboratory characteristics of HCV infection in patients with oncohematological malignancies. Materials and Methods: The study included 106 patients with a positive serum HCV antibody (anti-HCV) test result, who were examined or treated in 5 specialized oncohematological units of different hospitals in Saint Petersburg in 2018β2019.Laboratory tests included: ALT and AST activity, qualitative (with sensitivity of 60 IU/ml) and quantitative determination of HCV RNA, as well as HCV genotyping by real-time PCR. The presence and the grade of liver fibrosis according to the METAVIR scale were evaluated by indirect elastography on Fibroscan. Results: Men were predominant (62,2%), and most of patients (67%) were of young and middle age (18-59 years old). HCV infection was confirmed in 68% patients, and in 41.7% of them HCV genotype 3 was detected. HCV RNA was not detected in 32% cases, suggesting the spontaneous clearance of the virus. Severe liver fibrosis (F3) or cirrhosis (F4) were found in 40% patients with confirmed viremia. In most patients, the normal ALT activity level was registered. 86% patients diagnosed with HCV infection were followed up by an infectious disease specialist until the present study. 19% patients received antiviral therapy for HCV infection. Conclusion: A significant proportion of patients with advanced liver fibrosis and HCV 3 genotype, causing the greatest difficulties in antiviral treatment for HCV infection, was revealed. Prescription of direct-acting antiviral agents in the early terms after establishment of the diagnosis is reasonable